Prostate Cancer Diagnostics
Prostate Cancer Diagnostics
Advertisement
Katy MarshallProstate Cancer Diagnostics | July 15, 2024
Patients were sorted into groups based on modifiable lifestyle behaviors and genetic risk.
Read More
Emily MenendezProstate Cancer Diagnostics | June 21, 2024
Researchers trained and externally validated an AI system to detect Gleason grade group 2 or higher cancers.
Jérémie Calais, MD, PhDRLT | June 20, 2024
Dr. Calais provides his list of the clinical trials of interest on imaging, RLT, and prostate cancer from the SNMMI meeting.
Jérémie Calais, MD, PhDRLT | June 20, 2024
Dr. Calais shares his thoughts on the sessions or abstracts that are of the most importance for practicing GU oncologists.
Zachary BessetteProstate Cancer Diagnostics | June 11, 2024
New research provides evidence of 18F-rhPSMA-7 leading to more favorable disease outcomes for patients with BCR after RP.
Brandon TwyfordProstate Cancer Diagnostics | June 11, 2024
COBRA trial shows 64Cu-SAR-bisPSMA improves detection of recurrent prostate cancer with high specificity.
Tian Zhang, MDProstate Cancer Diagnostics | June 10, 2024
Dr. Zhang expands on treatment outcomes for patients with prostate cancer after imaging with Ga68-PSMA-PET.
Katy MarshallProstate Cancer Diagnostics | May 21, 2024
Researchers found no differences between the proportion of distant metastases in the salvage PBRT and WPRT groups.
Eric Li, MDProstate Cancer Diagnostics | May 8, 2024
Dr. Li highlights the significance of adverse pathologic features at radical prostatectomy for AS-eligible patients.
Yaw A. Nyame, MD, MS, MBAProstate Cancer Diagnostics | May 7, 2024
Dr. Nyame shared highlights from his presentation on PC screening in high-risk groups as part of an AUA plenary session.
Katy MarshallProstate Cancer Diagnostics | May 3, 2024
The utility of cADT in patients with prostate cancer with clinical relapse at PSMA PET is unknown.
Gillian Vandekerkhove, PhDProstate Cancer Diagnostics | April 25, 2024
Dr. Vandekerkhove explains her research on genomic testing in prostate cancer.
Emily MenendezProstate Cancer Diagnostics | April 24, 2024
The benefits of PSA screening alone are offset by excess negative biopsies and the over-detection of low-grade cancers.
Andrei Iagaru, MDProstate Cancer Diagnostics | April 16, 2024
Dr. Iagaru discusses the safety findings and clinical implications of his research.
Gary Ulaner, MD, PhD, FSNMMI, FACNMProstate Cancer Diagnostics | April 16, 2024
Dr. Ulaner highlights 2 new clinical trials for prostate cancer staging and treatment at Hoag: MIRROR and 177Lu-PNT2002.
Leonard Gomella, MD, FACSProstate Cancer Diagnostics | April 10, 2024
Dr. Gomella tells his journey to becoming a urologist, the importance of multidisciplinary care, and challenges in the field.
Emily MenendezProstate Cancer Diagnostics | April 10, 2024
Prostate-specific antigen density was the only clinical variable significantly associated with csPCa other than PI-RADS 5.
Leah LawrenceProstate Cancer Diagnostics | April 8, 2024
We spoke with several researchers involved in exploring the clinical utility of liquid biopsy for genitourinary cancers.
Katy MarshallProstate Cancer Diagnostics | March 25, 2024
Cohort 4 of the trial is the final dose-escalation phase and will be followed by a dose-expansion phase.
Jérémie Calais, MD, PhDProstate Cancer Diagnostics | March 21, 2024
The panel continues discussing their phase 3 PSMA PET/CT trial expectations for the final data readout in 2025.
Advertisement
Advertisement
Advertisement